Skip to main content
PepStack
Blutwerte · Marker

Hämatokrit

Hematocrit · HCT · PCV

BlutbildZeitabhängig
Einheit:
L/L
Abbreviation
HKT / HCT

Hematocrit quantifies the proportion of blood volume that is occupied by red blood cells.

Reference Ranges

Reference
0.36–0.5L/L
0.36
0.4
0.5
LowNormalHigh
Reference
Optimal
Unit · L/L

Reference ranges can vary based on age, sex, and altitude. Typically higher in males and lower in females.

Overview

Übersicht

Hematocrit (HCT) is a blood biomarker that measures the proportion of blood volume occupied by red blood cells. It is a crucial component of the complete blood count (CBC) and provides insight into the oxygen-carrying capacity of the blood. Researchers have found that hematocrit levels are indicative of various physiological and pathological states. Clinically, hematocrit is important for diagnosing and monitoring conditions such as anemia, polycythemia, dehydration, and blood loss. Elevated hematocrit levels can reflect conditions like polycythemia vera or chronic obstructive pulmonary disease (COPD), while low levels may indicate anemia or overhydration. In the context of athletic performance and biohacking, hematocrit is relevant as it can influence endurance and oxygen delivery to tissues. Athletes may seek to optimize hematocrit levels to enhance performance, although this must be done cautiously to avoid health risks. Hematocrit levels can be influenced by factors such as hydration status, altitude, and certain medications. Researchers observed that time-of-day variations and recent physical activity can also affect hematocrit readings, making standardized testing conditions important for accurate assessment.

Klinische Bedeutung

Elevated hematocrit levels may indicate dehydration, polycythemia vera, or chronic hypoxia. Reduced hematocrit levels can suggest anemia, blood loss, or overhydration.

Dynamics

Trend Interpretation

Rising Values

Progressively rising hematocrit values may suggest dehydration or polycythemia. Re-test in 4 weeks if outside the optimal range.

Falling Values

Progressively falling hematocrit values may indicate anemia or blood loss.

Re-test Interval

4 weeks if outside optimal range

Etiology

Causes — High & Low

Cause

Elevated Levels

  • Dehydration
  • Polycythemia vera
  • Chronic obstructive pulmonary disease
  • High altitude
  • Smoking
Cause

Low Levels

  • Anemia
  • Blood loss
  • Overhydration
  • Chronic kidney disease
  • Nutritional deficiencies
Protocol

How to Optimize

Lever

Lifestyle

  • Maintain adequate hydration
  • Avoid smoking
  • Engage in regular aerobic exercise
Lever

Nutrition

  • Increase iron-rich foods
  • Consume vitamin B12-rich foods
  • Ensure adequate folate intake
Lever

Supplementation

  • Iron supplements
  • Vitamin B12
  • Folate

Note:

Consult a physician before starting iron supplementation, especially if not diagnosed with iron deficiency.

Testing Guidelines

✓Fasting Not Required
🕐Time-Sensitive

Hematocrit levels can vary with diurnal changes; morning measurements are often preferred.

Testing Frequency

Annually for healthy adults, more frequently if monitoring a known condition.

Interfering Factors

  • Recent intense exercise
  • Dehydration
  • Altitude changes

Related Peptides & Hormones

Erythropoietin

May affect

hormone or peptide

Open Research Questions

Current research suggests that reference ranges for hematocrit in the context of hematopoietic cell transplantation (HCT) remain poorly defined, particularly regarding optimal targets for predicting complications like graft-versus-host disease (GVHD). Researchers have not yet established the impact of confounding factors such as inflammation and concurrent infections on hematocrit levels post-HCT. Additionally, clinical questions remain unanswered about the role of hematocrit as a prognostic biomarker for long-term outcomes in HCT recipients.

50 Research Publications

798

Total Citations

24

Human/RCT

3.0

Avg. Influence

2025

Latest

Sort
Filter
#01

An early-biomarker algorithm predicts lethal graft-versus-host disease and survival.

HumanInfluence7.0
236
Researchers developed a biomarker algorithm based on blood samples taken seven days after HCT to predict severe graft-versus-host disease (GVHD) and nonrelapse mortality. The algorithm successfully identified high-risk patients, demonstrating its potential for improving patient management.
View on PubMed
#02

Biomarker Panel for Chronic Graft-Versus-Host Disease.

HumanInfluence10.0
132
Researchers aimed to identify biomarkers for chronic graft-versus-host disease (cGVHD) after HCT. They found a four-biomarker panel that effectively predicts cGVHD diagnosis and severity, which could aid in patient stratification and management.
View on PubMed
#03

Biomarkers for acute GVHD: can we predict the unpredictable?

Review
54
This study focused on identifying blood biomarkers for acute graft-versus-host disease (GVHD) to improve diagnosis and management. Researchers observed that combining novel biomarkers with traditional cytokines may enhance predictive capabilities for patient outcomes.
View on PubMed
#04

Plasma biomarkers in graft-versus-host disease: a new era?

Review
49
This review summarized recent proteomics approaches aimed at identifying plasma biomarkers for acute graft-versus-host disease (GVHD). Researchers noted the potential for these biomarkers to provide diagnostic, prognostic, and predictive value, which could enhance therapeutic decisions for patients.
View on PubMed
#05

Approach to Interpreting Common Laboratory Pathology Tests in Transgender Individuals.

ReviewInfluence2.0
37
This review discussed the interpretation of laboratory tests in transgender individuals undergoing hormone therapy. Researchers highlighted the need to adjust reference ranges for hematocrit and other tests based on the individual's affirmed gender to improve clinical care and outcomes.
View on PubMed
#06

Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT.

Human
34
This position paper addressed the management of splenomegaly in myelofibrosis patients before allogeneic HCT. Researchers found that significant splenic enlargement is linked to higher risks of graft failure and mortality, highlighting the need for assessment and potential treatment of splenomegaly prior to transplantation.
View on PubMed
#07

Current Definitions and Clinical Implications of Biomarkers in Graft-versus-Host Disease.

Review
28
This review focused on the definitions and clinical implications of biomarkers in graft-versus-host disease (GVHD) following hematopoietic cell transplantation (HCT). Researchers found that while many biomarkers have been identified, none are yet qualified for clinical use. The study emphasizes the need for clarity in biomarker definitions to improve clinical management of GVHD.
View on PubMed
#08

Hepatic complications of hematopoietic cell transplantation.

ReviewInfluence1.0
27
This study examined the complications related to liver disease following hematopoietic cell transplantation (HCT). Researchers found that acute liver dysfunction is often indicated by early liver function test results, with common causes including graft-versus-host disease and infections. Prompt diagnosis through laboratory tests and imaging is crucial for effective management.
View on PubMed
#09

Idiopathic Intracranial Hypertension and Anemia: A Matched Case-Control Study.

HumanInfluence2.0
24
Researchers conducted a matched case-control study to investigate the association between idiopathic intracranial hypertension and anemia. They found no significant differences in complete blood count values between patients with idiopathic intracranial hypertension and controls.
View on PubMed
#10

Real-world treatments and thrombotic events in polycythemia vera patients in the USA.

HumanInfluence2.0
23
Researchers analyzed treatment patterns in polycythemia vera (PV) patients and found that maintaining hematocrit levels below 45% is crucial to prevent thrombotic events. The study revealed that a significant portion of patients had suboptimal HCT control, with many experiencing thrombotic events post-treatment.
View on PubMed

Publication Trend

Research publications about Hämatokrit over time

9total
1
'05
1
'07
1
'08
1
'13
1
'16
2
'17
1
'19
1
'20

Track your bloodwork in PepStack

Log lab results, track trends and optimize your biomarkers over time.

Legal Disclaimer

This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer